<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217473</url>
  </required_header>
  <id_info>
    <org_study_id>TILT-T215</org_study_id>
    <nct_id>NCT04217473</nct_id>
  </id_info>
  <brief_title>TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma</brief_title>
  <acronym>TUNINTIL</acronym>
  <official_title>A Phase 1, Open-Label, Dose-Escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 in Melanoma Patients Receiving Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TILT Biotherapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TILT Biotherapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase 1, first-in-human (FIH), dose-escalation, multicenter,&#xD;
      multinational trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy and&#xD;
      in association with T-cell therapy with TILs in metastatic melanoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the trial is to evaluate the safety of TILT-123. The approach has&#xD;
      the potential to a) increase the efficacy of adoptive T-cell therapy, b) remove the need for&#xD;
      toxic pre- and post-conditioning regimens, c) yield the combined anti-tumor benefits of armed&#xD;
      oncolytic viruses and T-cell therapy.&#xD;
&#xD;
      Dose escalation of TILT-123 injection will take place between cohorts not intra-patient and&#xD;
      will be determined based on Dose Limiting Toxicities (DLTs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open-label, single arm, dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with any (serious and non-serious) Adverse Events prior to TIL administration.</measure>
    <time_frame>36 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal laboratory values prior to TIL administration.</measure>
    <time_frame>36 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with vital sign abnormalities prior to TIL administration.</measure>
    <time_frame>36 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12- lead electrocardiograms (ECGs) Adverse Events prior to TIL administration.</measure>
    <time_frame>36 days</time_frame>
    <description>Any clinically significant adverse changes on the ECG will be reported as Adverse Events.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>TILT-123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive administrations of TILT-123. Patients will also receive Tumor Infiltrating Lymphocytes (TILs) during the treatment phase.&#xD;
Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TILT-123</intervention_name>
    <description>TNFalpha and IL-2 coding oncolytic adenovirus TILT-123</description>
    <arm_group_label>TILT-123</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent before any trial-related activities.&#xD;
&#xD;
          -  Male or female, between 18-75 years of age (both included).&#xD;
&#xD;
          -  Pathologically confirmed previously treated refractory or recurrent stage 3-4&#xD;
             melanoma, which cannot be treated with curative intent with available therapies.&#xD;
&#xD;
          -  At least one prior line of medical treatment is required (for example checkpoint&#xD;
             inhibitors, kinase inhibitors, interleukin-2). Multiple prior therapies (e.g. surgery,&#xD;
             checkpoint inhibitors, kinase inhibitors, interleukin-2, interferon, chemotherapy,&#xD;
             radiation) are allowed.&#xD;
&#xD;
          -  A &gt; 9 mm tumor (in diameter, typically a minimum of 1 cm3 in volume) without signs of&#xD;
             necrosis must be available for biopsy/operation to enable growing of TILs.&#xD;
&#xD;
          -  At least one additional tumor (&gt;14 mm in diameter) must be available for injections&#xD;
             and biopsies for correlative analyses. The disease burden must be measurable, but does&#xD;
             not need to fulfil RECIST 1.1.&#xD;
&#xD;
          -  Eligible for adoptive T-cell therapy with tumor infiltrating lymphocytes&#xD;
&#xD;
        Adequate hepatic, cardiac and renal functions as following:&#xD;
&#xD;
          1. Platelets &gt; 75 000/mm3&#xD;
&#xD;
          2. Haemoglobin ≥ 100 g/L.&#xD;
&#xD;
          3. AST and ALT &lt; 3 x ULN.&#xD;
&#xD;
          4. GFR &gt;60 ml/min (Cockcroft-Gault formula).&#xD;
&#xD;
          5. Leukocytes (WBC) &gt; 3,0&#xD;
&#xD;
          6. Bilirubin &lt;1.5 x ULN&#xD;
&#xD;
               -  Men and women must be willing to use adequate forms of contraception from&#xD;
                  screening, during the trial, and for a minimum of 90 days after end of treatment,&#xD;
                  in accordance with the following:&#xD;
&#xD;
               -  Women of childbearing potential: Barrier contraceptive method (i.e. condom) must&#xD;
                  be used in addition to one of the following methods: Intrauterine devices or&#xD;
                  hormonal contraception (oral contraceptive pills, implants, transdermal patches,&#xD;
                  vaginal rings or long-acting injections).&#xD;
&#xD;
               -  Women not of childbearing potential: Barrier contraceptive method (i.e. condom)&#xD;
                  must be used.&#xD;
&#xD;
               -  Men: Barrier contraceptive method (i.e. condom) must be used.&#xD;
&#xD;
               -  Demonstrated WHO performance score of 0-1 at screening.&#xD;
&#xD;
               -  Life expectancy time longer than 3 months.&#xD;
&#xD;
               -  Capable of understanding and complying with parameters as outlined in the&#xD;
                  protocol.&#xD;
&#xD;
               -  BRAF negative or positive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of immunosuppressive medications (corticosteroids or drugs used in treatment of&#xD;
             autoimmune disease). Exempted are the following which can be allowed at screening and&#xD;
             during the trial: replacement corticosteroids if e.g. the patient has adrenal&#xD;
             insufficiency after prior immunotherapy; pulmonal and topical treatments; up to 20 mg&#xD;
             of prednisone/prednisolone.&#xD;
&#xD;
          -  History of another active invasive cancer as judged by the investigator within the&#xD;
             past 3 years except basalioma.&#xD;
&#xD;
          -  Treated with any anti-cancer therapy for melanoma 30 days prior to enrolment.&#xD;
             Anti-cancer therapy for melanoma is defined as anti-cancer agents (immunotherapy,&#xD;
             signal-transduction inhibitors [e.g. BRAF and MEK inhibitors], cytotoxic&#xD;
             chemotherapy), radiotherapy and investigational agents. An investigational agent is&#xD;
             any drug or therapy that is currently not approved for use in humans.&#xD;
&#xD;
          -  Uncontrolled cardiac or vascular diseases.&#xD;
&#xD;
          -  History of heart attack or cerebral stroke within the previous 12 months before&#xD;
             screening or is not recovered from an older heart attack or cerebral stroke.&#xD;
&#xD;
          -  LDH value &gt; 3 x ULN.&#xD;
&#xD;
          -  History of hepatic dysfunction, hepatitis or HIV.&#xD;
&#xD;
          -  History of coagulation disorder.&#xD;
&#xD;
          -  Any other disease which prevent participation in the opinion of the investigator.&#xD;
&#xD;
          -  Female patients who are pregnant, breastfeeding or intends to become pregnant.&#xD;
&#xD;
          -  Untreated brain metastases. Treated brain metastases which have not progressed in 3&#xD;
             months prior to screening are allowed.&#xD;
&#xD;
          -  Previously treated with any oncolytic adenovirus that was administered intratumorally.&#xD;
&#xD;
          -  Previously treated with adoptive cell therapy.&#xD;
&#xD;
          -  Allergy to TILT-123, TIL, or ingredients present in the investigational medicinal&#xD;
             products.&#xD;
&#xD;
          -  Administered an investigational medicinal product or device in another clinical trial&#xD;
             within 30 days prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inge Marie Svane</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCIT, Herlev Hospital, Copenhagen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brigitte Dréno</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nantes, Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Herlev Hospital</last_name>
    <phone>+45 38 68 38 68</phone>
    <email>herlevhospital@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Inge Marie Svane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brigitte Dréno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oncolytic virus</keyword>
  <keyword>T-cell therapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>TILT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

